- Organizations: Formosa Pharmaceuticals
Products
Harrow acquires U.S. rights to clobetasol propionate for postop inflammation and pain
Commercial rights for the newly-named BYQLOVI reportedly purchased from Formosa; plans include a Q4 2025 launch.
Products
Eyenovia launches clobetasol propionate suspension in US
Originally developed by Formosa, the solution is indicated to treat pain and inflammation following ocular surgery.
Products
Formosa to ship clobetasol propionate to US for commercialization
With exclusive rights owned by Eyenovia, the FDA-approved formulation is indicated to treat pain and inflammation following ocular surgery.
Pipeline
Eyenovia and Formosa to co-develop clobetasol propionate solution for DED
Partnership will feature FDA-approved eye drop and Optejet delivery system for precision dosing.
Products
FDA approves clobetasol propionate suspension for postop inflammation and pain
Developed by Formosa with exclusive U.S rights owned by Eyenovia, the novel ophthalmic APP13007 is expected to launch mid-2024.
Pipeline
Eyenovia acquires US rights to Formosa's APP13007
Worth up to $86 million, the deal could also include payments following a potential FDA approval.
Pipeline